JP2009506301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506301A5 JP2009506301A5 JP2008524596A JP2008524596A JP2009506301A5 JP 2009506301 A5 JP2009506301 A5 JP 2009506301A5 JP 2008524596 A JP2008524596 A JP 2008524596A JP 2008524596 A JP2008524596 A JP 2008524596A JP 2009506301 A5 JP2009506301 A5 JP 2009506301A5
- Authority
- JP
- Japan
- Prior art keywords
- pif
- affinity reagent
- abundance
- protein isoform
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000012902 Nervous system disease Diseases 0.000 claims description 13
- 208000025966 Neurological disease Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 13
- 102000001708 Protein Isoforms Human genes 0.000 claims 10
- 108010029485 Protein Isoforms Proteins 0.000 claims 10
- 239000003153 chemical reaction reagent Substances 0.000 claims 10
- 238000012360 testing method Methods 0.000 claims 6
- GLXYOFXNKBTMQL-YKCHQESGSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)CCC1 GLXYOFXNKBTMQL-YKCHQESGSA-N 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229930195712 glutamate Natural products 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 5
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516058.5A GB0516058D0 (en) | 2005-08-04 | 2005-08-04 | New protein isoforms and uses thereof |
| US72208705P | 2005-09-30 | 2005-09-30 | |
| PCT/GB2006/050232 WO2007015113A2 (en) | 2005-08-04 | 2006-08-04 | New protein isoforms of the pif-family and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009506301A JP2009506301A (ja) | 2009-02-12 |
| JP2009506301A5 true JP2009506301A5 (enExample) | 2009-09-17 |
Family
ID=34984093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524596A Pending JP2009506301A (ja) | 2005-08-04 | 2006-08-04 | Ｐｉｆファミリーの新たなタンパク質アイソフォーム及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100223678A1 (enExample) |
| EP (1) | EP1987356A2 (enExample) |
| JP (1) | JP2009506301A (enExample) |
| GB (1) | GB0516058D0 (enExample) |
| WO (1) | WO2007015113A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502628B1 (en) | 2006-06-23 | 2016-12-14 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in cancer |
| WO2010060186A1 (en) | 2008-11-03 | 2010-06-03 | Alethia Biotherapeutics Inc. | Antibodies that specifically block the biological activity of a tumor antigen |
| WO2010096331A1 (en) | 2009-02-11 | 2010-08-26 | Duke University | Sensors incorporating antibodies and methods of making and using the same |
| JP5433341B2 (ja) * | 2009-08-04 | 2014-03-05 | ホーユー株式会社 | 等電点電気泳動方法及び粗雑物除去の判定方法 |
| JP5190423B2 (ja) * | 2009-08-04 | 2013-04-24 | ホーユー株式会社 | ２次元電気泳動方法 |
| DK3173427T3 (da) | 2011-03-31 | 2019-08-05 | Adc Therapeutics Sa | Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf |
| MX2014002144A (es) * | 2011-08-26 | 2014-03-31 | Hoffmann La Roche | Metodo para predecir el beneficio clinico del tratamiento de los transtornos del desarrollo neurologico, neurologicos o neuropsiquiatricos. |
| HRP20190946T1 (hr) | 2012-01-09 | 2019-07-26 | Adc Therapeutics Sa | Sredstva za liječenje trostruko negativnog raka dojke |
| US9244946B2 (en) | 2012-11-26 | 2016-01-26 | International Business Machines Corporation | Data mining shape based data |
| US10407716B2 (en) | 2014-03-13 | 2019-09-10 | Duke University | Electronic platform for sensing and control of electrochemical reactions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319687B1 (en) * | 1992-09-24 | 2001-11-20 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene |
| US6613740B1 (en) * | 1997-02-07 | 2003-09-02 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Activity dependent neurotrophic factor III (ADNF III) |
| US20040038877A1 (en) * | 2001-10-02 | 2004-02-26 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| EP1408333A3 (en) * | 2001-10-03 | 2006-10-25 | Pfizer Products Inc. | Diagnosis and treatment of Alzheimer's disease |
| AU2003235789A1 (en) * | 2002-01-11 | 2003-07-24 | Xantos Biomedicine Ag | Novel apoptosis-inducing dna sequences |
| US20090162363A1 (en) * | 2003-08-07 | 2009-06-25 | Sofia Patricia Becerra | Pedf-r receptor and uses |
| JP2005132738A (ja) * | 2003-10-28 | 2005-05-26 | Protein Express:Kk | アルツハイマー病のタンパク質分子レベルにおける検出方法 |
-
2005
- 2005-08-04 GB GBGB0516058.5A patent/GB0516058D0/en not_active Ceased
-
2006
- 2006-08-04 EP EP06765380A patent/EP1987356A2/en not_active Withdrawn
- 2006-08-04 US US11/989,828 patent/US20100223678A1/en not_active Abandoned
- 2006-08-04 WO PCT/GB2006/050232 patent/WO2007015113A2/en not_active Ceased
- 2006-08-04 JP JP2008524596A patent/JP2009506301A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Laroche et al. | Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia | |
| Ohtsuka et al. | Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging | |
| US20140303041A1 (en) | In vitro diagnostic devices for nervous system injury and other neural disorders | |
| Bowser et al. | Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations | |
| Hanly et al. | Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. | |
| JP5241710B2 (ja) | 神経変性障害の診断および早期診断のためのｉｎｖｉｔｒｏマルチパラメータ測定法 | |
| EP3115785A2 (en) | Process to diagnose or treat brain injury | |
| CN107533048A (zh) | 用于诊断脑损伤或神经退行性变的方法和组合物 | |
| Castañeyra-Ruiz et al. | Cerebrospinal fluid levels of tumor necrosis factor alpha and aquaporin 1 in patients with mild cognitive impairment and idiopathic normal pressure hydrocephalus | |
| US20140024053A1 (en) | Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury | |
| US20220057409A1 (en) | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair | |
| KR20170062478A (ko) | 우울증 치료약의 선택지를 예측하는 방법 | |
| JP2009506301A5 (enExample) | ||
| KR20230010687A (ko) | 알츠하이머 병 평가용 단백질 마커 | |
| González-Quevedo et al. | Increased serum S-100B and neuron specific enolase—Potential markers of early nervous system involvement in essential hypertension | |
| JP2018132526A (ja) | 大うつ病性障害及び双極性障害のマーカー、検査方法、検査キット、及び治療薬のスクリーニング方法。 | |
| Blandford et al. | Interleukin-1 receptor antagonist: an exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis | |
| JP2009515183A5 (enExample) | ||
| JP5295101B2 (ja) | 神経変性疾患の経過及び予後の評価指標を提供するｉｎｖｉｔｒｏ方法 | |
| JP5267452B2 (ja) | 精神障害および／または腸のディスバイオシスのインビトロまたはエクスビボ診断方法 | |
| US7709215B2 (en) | Method for diagnosing and treating acute joint injury | |
| US20080076140A1 (en) | Biomarkers of Alzheimer's Disease | |
| US20060205024A1 (en) | Method to diagnose and evaluate progression of Alzheimer's disease | |
| CN103210312A (zh) | 通过软骨酸性蛋白1 检测脑梗塞的方法 | |
| US20140377763A1 (en) | Brain damage marker |